SV joins CRUK on a $250M-plus fund with an eye on de­vel­op­ing new can­cer drugs

With its de­men­tia fund up and run­ning, SV Health In­vestors is kick­start­ing a new, spe­cial­ized $250 mil­lion-plus fund to gam­ble on new can­cer biotechs — dou­bling down on one of the hottest fields in bio­phar­ma. And they’re do­ing it with a big con­tri­bu­tion from Can­cer Re­search UK to help seed the ef­fort.

CRUK is con­tribut­ing $25 mil­lion to the cause, and open­ing some doors for SV along the way. The non-prof­it re­search group has a pipeline of 30 drugs it’s col­lab­o­rat­ing on in pre­clin­i­cal or clin­i­cal de­vel­op­ment, build­ing on the 8 ap­proved ther­a­pies that have helped fu­el its sci­en­tif­ic mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER